Merck announces that it will present new data on four approved oncology drugs and four drug candidates in development at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.

These data will cover more than 25 cancer types and highlight Merck's progress in clinical research.

Key presentations will include updated and long-term follow-up data on Keytruda, including advanced gastrointestinal cancer, advanced melanoma, metastatic bladder cancer, and early-stage non-small cell lung cancer.

Merck will also present data on various candidates currently under investigation, often in combination with Kerytruda.

These will include individualized neoantigen therapies developed with Moderna, an anti-TIGIT therapy, an anti-TROP2 antibody-drug conjugate, and an ADC directed against HER3 in collaboration with Daiichi Sankyo.

Copyright (c) 2024 All rights reserved.